Welcome to the newest instalment of Flagged Events: Funding segment. We’ll cover a sample of the drug companies with funding announcements in the previous month across different global markets. These include IPO announcements, grants, royalty payments, investments, and more.
Here are some of the pharma/biotech companies headquartered in California that announced funding activity:
La Jolla’s clinical stage Inhibrx filed Form S-1 for a planned public offering in the USA. The pricing and date have yet to be announced. The announcement comes after the May closing of a $40 million investment from Viking Global Investors.
City: La Jolla
Website: https://inhibrx.com/
Primary Therapeutic Area: Oncology
Preclinical Activity in the past 12 months: Yes
Have a Zymewire account? Click here to view Inhibrx’s global activity!
After filing SEC Form S-1 at the end of May, clinical stage Akero announced the pricing for their initial public offering of 6,612,500 common stock shares on June 20th. The IPO closed June 24th, with aggregate proceeds totalling $105.8 million ($16.00 per share).
City: San Francisco
Website: https://www.akerotx.com/
Primary Therapeutic Area: Liver Disease
Preclinical Activity in the past 12 months: No
Have a Zymewire account? Click here to view Akero’s global activity!
San Diego’s Ablexis LLC announced a non-exclusive licensing agreement with Zai Lab LLC for the use of Ablexis’ AlivaMab Mouse platform for antibody drug discovery and development. Ablexis licenses the platform to many of the major pharmaceutical companies, and also offer licensing to smaller biotechs.
City: San Diego
Website: https://www.ablexis.com/
Primary Therapeutic Area: CNS
Preclinical Activity in the past 12 months: No
Have a Zymewire account? Click here to view Ablexis’ global activity!
On June 3rd, a drug discovery partnership between Gilead and Chengdu’s HitGen was announced. The terms of the deal include an undisclosed upfront payment to HitGen, as well as milestone payments. The use of HitGen’s DNA-encoded chemical library platform will aid in the development of small molecule candidates in Gilead’s primary target areas.
City: Foster City
Website: https://www.gilead.com/
Primary Therapeutic Area: Infectious Disease
Preclinical Activity in the past 12 months: Yes
Have a Zymewire account? Click here to view Gilead’s global activity!
Cloudbreak received a Phase 2 SBIR grant payment of $809 052 from the National Eye Institute for the safety and pharmacokinetics evaluation of their CBT-001 candidate in the treatment of Pterygium.
City: Irvine
Website: http://cloudbreaktherapeutics.com
Primary Therapeutic Area: Ophthalmology
Preclinical Activity in the past 12 months: No
Have a Zymewire account? Click here to view Cloudbreak’s global activity!
Vivreon received a Phase 2 SBIR grant payment of $1.25 million from the National Institute on Aging. The funds will be used for lead optimization of their Ca2+ release-activated Ca2+ (CRAC) channel inhibitors for treatment of Alzheimers.
City: San Diego
Website: http://www.vivreonbiosciences.com/
Primary Therapeutic Area: Chronic Inflammatory Indications
Preclinical Activity in the past 12 months: Yes
Have a Zymewire account? Click here to view Vivreon’s global activity!
Redwood City’s AcelRx Pharmaceuticals announced the closing of $25 million in senior debt financing with Oxford Finance LLC on June 3rd. The fully funded loan will be used for the launch of DSUVIA, AcelRx’s recently approved (November 2018) sublingual sufentanil analgesic for severe acute pain. It will also be used for other credit facility repayment.
City: Redwood City
Website: https://www.acelrx.com/index.php
Primary Therapeutic Area: Pain Symptoms
Preclinical Activity in the past 12 months: No
Have a Zymewire account? Click here to view AcelRx’s global activity!
SEC Form D records indicate the receipt of $575 000 in equity financing towards a $1.58 million offer. The financing was received between May 24th and June 4th.
City: San Francisco
Website: http://www.phitherapeutics.com/
Primary Therapeutic Area: Dermatology
Preclinical Activity in the past 12 months: No
Have a Zymewire account? Click here to view Phi’s global activity!
If you’d like to track funding activities across the regions that matter to you, all without relying on a database, Zymewire is here to help. Put your prospecting and sales research on autopilot so that you can quickly identify and prioritize new opportunities. Reach out today, and stay tuned for the next instalment of Flagged Events: Funding. If you enjoy these articles, please feel free to give them a share through the social links below!